Clinical Trial Update: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IO102/IO103 in combination with nivolumab and relatlimab for melanoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IO102-IO103 (IO102-IO103)
• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING